308 Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol. 2008;103(1): 162-169. Lehmann FS, Burri E, Beglinger C. The role and utility of faecal markers in inflammatory bowel disease. Therap Adv Gastroenterol. 2015;8(1): 23-36. Sands BE. Biomarkers of Inflammation in Inflammatory Bowel Disease. Gastroenterology. 2015;149(5): 1275-1285.e2. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol. 2000;35(11): 1163-1169. Andre F, Andre C, Emery Y, Forichon J, Descos L, Minaire Y. Assessment of the lactulose-mannitol test in Crohn’s disease. Gut. 1988;29(4): 511-515. Ainsworth M, Eriksen J, Rasmussen JW, Schaffalitzky de Muckadell, OB. Intestinal permeability of 51Crlabelled ethylenediaminetetraacetic acid in patients with Crohn’s disease and their healthy relatives. Scand J Gastroenterol. 1989;24(8): 993-998. Arslan G, Atasever T, Cindoruk M, Yildirim IS. (51)CrEDTA colonic permeability and therapy response in patients with ulcerative colitis. Nucl Med Commun. 2001;22(9): 997-1001. Bjarnason I,O’MorainC, LeviAJ, PetersTJ. Absorptionof 51chromium-labeledethylenediaminetetraacetate in inflammatory bowel disease. Gastroenterology. 1983;85(2): 318-322. Jenkins AP, Nukajam WS, Menzies IS, Creamer B. Simultaneous administration of lactulose and 51Crethylenediaminetetraacetic acid. A test to distinguish colonic from small-intestinal permeability change. Scand J Gastroenterol. 1992;27(9): 769-773. Jenkins RT, Ramage JK, Jones DB, Collins SM, Goodacre RL, Hunt RH. Small bowel and colonic permeability to 51Cr-EDTA in patients with active inflammatory bowel disease. Clin Invest Med. 1988;11(2): 151-155. O’Morain CA, Abelow AC, Chervu LR, Fleischner GM, Das KM. Chromium 51-ethylenediaminetetraacetate test: a useful test in the assessment of inflammatory bowel disease. J Lab Clin Med. 1986;108(5): 430-435. Peled Y, Watz C, Gilat T. Measurement of intestinal permeability using 51Cr-EDTA. Am J Gastroenterol. 1985;80(10): 770-773. Pironi L, Miglioli M, Ruggeri E, Levorato M, Dallasta MA, Corbelli C, et al. Relationship between intestinal permeability to [51Cr]EDTA and inflammatory activity in asymptomatic patients with Crohn’s disease. Dig Dis Sci. 1990;35(5): 582-588. Turck D, Ythier H, Maquet E, Deveaux M, Marchandise X, Farriaux JP, et al. Intestinal permeability to [51Cr] EDTA in children with Crohn’s disease and celiac disease. J Pediatr Gastroenterol Nutr. 1987;6(4): 535-537. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, Van der Meer R. Dietary fructooligosaccharides increase intestinal permeability in rats. J Nutr. 2005;135(4): 837-842. Ten Bruggencate SJ, Bovee-Oudenhoven IM, Lettink-Wissink ML, Katan MB, van der Meer R. Dietary fructooligosaccharides affect intestinal barrier function in healthy men. J Nutr. 2006;136(1): 70-74. Sigthorsson G, Crane R, Simon T, Hoover M, Quan H, Bolognese J, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut. 2000;47(4): 527-532. Andersen R, Laerum F. Intestinal permeability measurements - a new application for water soluble contrast media? Acta Radiol Suppl. 1995;399: 247-252. Bjarnason I, Maxton D, Reynolds AP, Catt S, Peters TJ, Menzies IS. Comparison of four markers of intestinal permeability in control subjects and patients with coeliac disease. Scand J Gastroenterol. 1994;29(7): 630-639. Chapter 9 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38
RkJQdWJsaXNoZXIy MjY0ODMw